Increasing understanding of the pathogenesis of rheumatoid arthritis (RA) has remarkably
promoted the development of effective therapeutic regimens of RA. Nevertheless, the …

Nanomedicines with controlled drug release have received increasing attention as an
advanced therapeutic strategy for bone diseases. To traverse biological barriers towards …

There is a rapidly increasing interest in developing stimuli‐responsive nanomaterials for
treating a variety of diseases. By enabling the activation of function locally at the sites of …

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic joint
inflammation which ultimately leads to severe disability and premature mortality. It has a …

Drug delivery for osteoarthritis (OA) treatment is a continuous challenge because of their
poor bioavailability and rapid clearance in joints. Intra-articular (IA) drug delivery is a …

Palmitic acid-modified bovine serum albumin (PAB) was synthetized and found to own
remarkable scavenger receptor-A (SR-A) targeting ability in vitro and in vivo, through which …

Methotrexate (MTX) has been used as an anchor drug for the treatment of rheumatoid
arthritis (RA), while the patients with chronic MTX administration suffer from severe side …

Among a plethora of drug nanocarriers, biocompatible nanoscale metal–organic frameworks
(nanoMOFs) with a large surface area and an amphiphilic internal microenvironment have …

Rheumatoid arthritis (RA), a chronic autoimmune disease, is characterized by articular pain
and swelling, synovial hyperplasia, and cartilage and bone destruction. Conventional …

Rheumatoid arthritis (RA) is a debilitating autoimmune disease that causes chronic pain and
serious complications, presenting a significant challenge to treat. Promising approaches for …